Tildrakizumab Market Report 2026

Tildrakizumab Market Overview

• Tildrakizumab market size has reached to $1.76 billion in 2025 • Expected to grow to $3.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4% • Growth Driver: Rise In Autoimmune Disease Incidence Fueling The Growth Of The Market Due To Increasing Need For IL-23–Targeted Therapies • Market Trend: Transforming Treatment With Monoclonal Antibody Injections • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tildrakizumab Market?

Tildrakizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor. This inhibition prevents downstream inflammatory signaling, reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune conditions such as plaque psoriasis. The main indications of the tildrakizumab include plaque psoriasis, psoriatic arthritis, and other indications. Plaque psoriasis is a chronic autoimmune skin condition caused by the inflamed, and scaly patches of skin, known as plaques. The drug is available in injectable and oral forms and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It serves various end users, including hospitals, specialty clinics, and home care.

What Is The Tildrakizumab Market Growth Forecast?

The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to $3.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing demand for personalized autoimmune therapies, expansion of biologic pipeline indications, rising focus on long-term disease management, growing adoption of home-based biologic administration, increasing investment in immunology research. Major trends in the forecast period include increasing use of targeted biologic therapies, rising adoption of il-23 inhibitors, growing preference for long-acting injectable treatments, expansion of specialty biologic distribution channels, enhanced focus on patient-centric treatment regimens.

Global Tildrakizumab Market Segmentation

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications 2) By Dosage Form: Injectable, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Specialty Clinics, Homecare Subsegments: 1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis 2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis 3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications

What Are The Drivers Of The Tildrakizumab Market?

The increasing incidence of autoimmune diseases is expected to propel the growth of the tildrakizumab market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy tissues. Autoimmune diseases are increasing due to rising environmental triggers such as pollution and chemical exposure. Tildrakizumab is used in autoimmune disease by blocking the IL-23 pathway to reduce inflammation and control symptoms. For instance, in August 2024, according to the data from Public Health Scotland, a Scotland-based national organization, reported that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. Therefore, the increasing incidence of autoimmune diseases is driving the growth of the tildrakizumab industry. The improvement of healthcare facilities is expected to propel the growth of the tildrakizumab market going forward. Healthcare facilities are establishments that offer medical care and services, such as hospitals, clinics, and diagnostic centers, to treat and support patients. Healthcare facilities are improving due to several factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Enhancing healthcare facilities improves patient access to advanced biologic treatments, streamlines diagnosis and specialist referrals, ensures better cold chain management for biologics, and expands healthcare provider awareness, all of which collectively support the adoption and efficacy of tildrakizumab in treating chronic inflammatory conditions such as psoriasis. For instance, according to the American Hospital Association, a US-based non-profit organization, in 2024, the United States had 6,120 hospitals, reflecting an increase from 6,093 hospitals in 2022. Therefore, the improvement of healthcare facilities is driving the growth of the tildrakizumab industry.

Key Players In The Global Tildrakizumab Market

Major companies operating in the tildrakizumab market are Almirall S.A., Sun Pharmaceutical Industries Ltd., Novartis, Pfizer, Eli Lilly, Bristol Myers Squibb, Roche, Merck & Co, Janssen Biotech (Johnson & Johnson), Amgen, GSK, AbbVie, Sanofi, AstraZeneca, Innovent Biologics, Boehringer Ingelheim, LEO Pharma, Kyowa Kirin, Takeda Pharmaceutical, Regeneron Pharmaceuticals, Biocon Ltd.

Global Tildrakizumab Market Trends and Insights

Major companies operating in the tildrakizumab market are focusing on development of innovative formulations such as monoclonal antibody injection to enhance treatment efficacy and improve patient outcomes. Monoclonal antibody injection refers to the administration of laboratory-produced antibodies designed to target specific antigens in the body for therapeutic or preventive purposes. For instance, in May 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, received approval from the Chinese health authority, National Medical Products Administration (NMPA), for tildrakizumab injection used in treatment of plaque psoriasis. It works by targeting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that causes psoriasis. IL-23, tildrakizumab helps reduce inflammation and slow down excessive skin cell growth, improving symptoms such as redness, scaling, and plaque formation.

Regional Outlook

North America was the largest region in the tildrakizumab market in 2025. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tildrakizumab Market?

The tildrakizumab market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tildrakizumab Market Report 2026?

The tildrakizumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tildrakizumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.